Atossa Therapeutics (ATOS) 10-K 28 Mar 19 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 25, 2019	Jun. 30, 2018
Document Information [Line Items]
Entity Registrant Name	ATOSSA GENETICS INC
Entity Central Index Key	0001488039
Trading Symbol	atos
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		9,116,490
Entity Public Float			$ 4,874,099
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 10,380,493	$ 7,217,469
Restricted cash	110,000	55,000
Prepaid expenses	509,833	250,944
Research and development tax rebate receivable	518,098	358,277
Other current assets	30,942	16,344
Total current assets	11,549,366	7,898,034
Furniture and equipment, net	54,487	11,467
Intangible assets, net	99,375	75,686
Other assets	17,218	178,907
Total Assets	11,720,446	8,164,094
Current liabilities
Accounts payable	353,328	334,901
Accrued expenses	177,074	90,105
Payroll liabilities	935,070	784,867
Stock-based compensation liability	1,410,025
Other current liabilities	39,939	15,534
Total Current Liabilities	2,915,436	1,225,407
Commitments and contingencies (note 13)
Stockholders' equity
Preferred stock - $0.001 par value; 10,000,000 shares authorized, consisting of Series A convertible preferred stock- $0.001 par value; 4,000 shares authorized, and 0 shares outstanding as of December 31, 2018 and December 31, 2017; Series B convertible preferred stock- $0.001 par value; 25,000 and 0 shares authorized, and 2,379 and 0 shares issued and outstanding as of December 31, 2018 and December 31, 2017, respectively	2
Additional paid-in capital- Series B convertible preferred stock	2,378,997
Common stock - $0.18 par value; 175,000,000 shares authorized, and 5,846,552 and 2,651,952 shares issued and outstanding, as of December 31, 2018 and December 31, 2017, respectively	1,052,372	477,342
Additional paid-in capital	82,204,902	71,887,674
Accumulated deficit	(76,831,263)	(65,426,329)
Total Stockholders' Equity	8,805,010	6,938,687
Total Liabilities and Stockholders' Equity	$ 11,720,446	$ 8,164,094

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.18	$ 0.18
Common stock, authorized (in shares)	175,000,000	175,000,000
Common stock, issued (in shares)	5,846,552	2,651,952
Common stock, outstanding (in shares)	5,846,552	2,651,952
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	4,000	4,000
Preferred stock, outstanding (in shares)	0	0
Preferred stock, issued (in shares)	0
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	25,000	0
Preferred stock, outstanding (in shares)	2,379	0
Preferred stock, issued (in shares)	2,379	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating Expenses
Research and development	$ 4,209,981	$ 2,328,087
General and administrative	7,224,252	4,859,369
Impairment of intangible assets	0	461,715
Total operating expenses	11,434,233	7,649,171
Operating loss	(11,434,233)	(7,649,171)
Change in fair value of common stock warrants		(280,747)
Warrant financing expense		(192,817)
Other income	29,299	154
Loss before income taxes	(11,404,934)	(8,122,581)
Income taxes	0	0
Net loss	(11,404,934)	(8,122,581)
Deemed dividend attributable to preferred stock	(11,479,308)	(2,568,132)
Net loss applicable to common shareholders	$ (22,884,242)	$ (10,690,713)
Loss per common share -basic and diluted (in dollars per share)	$ (5.50)	$ (10.97)
Weighted average shares outstanding - basic and diluted (in shares)	4,157,746	974,773

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Sale of Common Stock in Class A Units [Member]Preferred Stock [Member]Series A Convertible Preferred Stock [Member]	Sale of Common Stock in Class A Units [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Sale of Common Stock in Class A Units [Member]Preferred Stock Additional Paid-in Capital [Member]Series A Convertible Preferred Stock [Member]	Sale of Common Stock in Class A Units [Member]Preferred Stock Additional Paid-in Capital [Member]Series B Convertible Preferred Stock [Member]	Sale of Common Stock in Class A Units [Member]Common Stock [Member]	Sale of Common Stock in Class A Units [Member]Common Stock Additional Paid-in Capital [Member]	Sale of Common Stock in Class A Units [Member]Retained Earnings [Member]	Sale of Common Stock in Class A Units [Member]	Preferred Stock [Member]Series A Convertible Preferred Stock [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Preferred Stock Additional Paid-in Capital [Member]Series A Convertible Preferred Stock [Member]	Preferred Stock Additional Paid-in Capital [Member]Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2016													315,576
Balance at Dec. 31, 2016													$ 56,804	$ 60,344,050	$ (57,303,748)	$ 3,097,106
Issuance of stock and warrants net of issuance costs (in shares)													1,483,333
Issuance of stock and warrants net of issuance costs													$ 267,001	5,895,587		6,162,588
Issuance of stock, net of issuance costs (in shares)					99,500
Issuance of stock, net of issuance costs					$ 17,910	$ 811,774		$ 829,684
Allocation of Class A unit proceeds to warrant liability														(328,350)		(328,350)
Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231 (in shares)									292
Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231									$ 4		3,234,769					3,234,773
Allocation of convertible preferred stock to warrants and beneficial conversion feature											(2,568,132)			1,284,066		(1,284,066)
Deemed dividend on convertible preferred stock											2,568,132			(2,568,132)
Conversion of convertible preferred stock to common stock (in shares)									(292)				(389,111)
Conversion of convertible preferred stock to common stock									$ (4)		(3,234,769)		$ (70,040)	(3,164,733)
Conversion of convertible preferred stock to common stock (in shares)									292				389,111
Conversion of convertible preferred stock to common stock									$ 4		3,234,769		$ 70,040	3,164,733
Reclassification of warrant liability upon exercise of common stock warrants (in shares)													124,236
Reclassification of warrant liability upon exercise of common stock warrants													$ 22,362	1,870,798		1,893,160
Issuance of common stock upon warrant exercise for cash on liability warrant exercise (in shares)													240,196
Issuance of common stock upon warrant exercise for cash on liability warrant exercise													$ 43,225	706,008		749,233
Amortization of commitment shares														(79,410)		(79,410)
Compensation cost for stock options granted														786,550		786,550
Net loss															(8,122,581)	(8,122,581)
Balance (in shares) at Dec. 31, 2017													2,651,952
Balance at Dec. 31, 2017													$ 477,342	71,887,674	(65,426,329)	6,938,687
Deemed dividend on convertible preferred stock											(2,568,132)			2,568,132
Issuance of stock and warrants net of issuance costs (in shares)										13,624
Issuance of stock and warrants net of issuance costs										$ 14		6,926,778		5,363,759		12,290,551
Allocation of convertible preferred stock to warrants and beneficial conversion feature												(4,782,100)		4,782,100
Deemed dividend on convertible preferred stock												11,479,308		(11,479,308)
Conversion of convertible preferred stock to common stock (in shares)										(11,245)			(3,194,600)
Conversion of convertible preferred stock to common stock										$ (12)		(11,244,989)	$ (575,030)	(10,669,971)
Conversion of convertible preferred stock to common stock (in shares)										11,245			3,194,600
Conversion of convertible preferred stock to common stock										$ 12		11,244,989	$ 575,030	10,669,971
Amortization of commitment shares														(72,790)		(72,790)
Compensation cost for stock options granted														1,053,496		1,053,496
Net loss															(11,404,934)	(11,404,934)
Balance (in shares) at Dec. 31, 2018										2,379			5,846,552
Balance at Dec. 31, 2018										$ 2		2,378,997	$ 1,052,372	82,204,902	(76,831,263)	8,805,010
Deemed dividend on convertible preferred stock												$ (11,479,308)		$ 11,479,308

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parentheticals) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Sale of Common Stock in Class A Units [Member]
Issuance of common stock, issuance costs		$ 65,816
Issuance of common stock and warrants, issuance costs	$ 1,333,449	768,412
Issuance of common stock, issuance costs		$ 267,231

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (11,404,934)	$ (8,122,581)
Adjustments to reconcile net loss to net cash used in operating activities
Compensation cost for stock options granted	1,053,496	786,550
Loss on disposal of assets		17,695
Impairment of intangible assets	0	461,715
Depreciation and amortization	44,197	128,994
Change in fair value of common stock warrants		280,747
Warrant financing expense		192,817
Change in stock-based compensation liability	1,410,025
Changes in operating assets and liabilities:
Prepaid expenses	(258,889)	(79,343)
Research and development tax rebate receivable	(159,821)	(358,277)
Other assets	74,301	(80,408)
Accounts payable	18,427	80,581
Payroll liabilities	150,203	14,968
Accrued expenses	86,969	73,141
Other current liabilities	24,405	9,451
Net cash used in operating activities	(8,961,621)	(6,593,950)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of furniture and equipment	(110,906)
Net cash used in investing activities	(110,906)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of Series B convertible preferred stock and warrants, net of issuance costs	12,290,551
Proceeds from issuance of Class A and Class B Units, net of issuance costs		3,871,636
Proceeds from exercise of warrants		749,233
Proceeds from issuance of common stock and warrants, net of issuance costs		6,162,588
Net cash provided by financing activities	12,290,551	10,783,457
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	3,218,024	4,189,507
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE	7,272,469	3,082,962
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	10,490,493	7,272,469
SUPPLEMENTAL DISCLOSURES
Interest Paid		330
NONCASH INVESTING AND FINANCING ACTIVITIES
Amortization of commitment shares	$ 72,790	$ 79,410

Note 1 - Nature of Operations

Note 1 - Nature of Operations	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Nature of Operations [Text Block]	1: Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009, December 31.

Note 2 - Liquidity and Capital

Note 2 - Liquidity and Capital Resources	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2: LIQUIDITY The Company has incurred net losses and negative operating cash flows since inception. For the year ended December 31, 2018, $11.4 $9.0 December 31, 2018, $10.4 $8.6 March 2019, $11.3 March 25, 2019, $19.3 not March 2019, one not may not may

Note 3 - Summary of Accounting

Note 3 - Summary of Accounting Policies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	NOTE 3: Basis of Presentation: The accompanying consolidated financial statements have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the financial statements of Atossa Genetics Inc. and its wholly-owned subsidiaries. All significant intercompany account balances and transactions have been eliminated in consolidation. On April 20, 2018, 1 12 12 one $0.18 not April 20, 2018. Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Recently Issued Accounting Pronouncements: In February 2016, No. 2016 02, Lease Accounting Topic 842. December 15, 2018 two one one January 1, 2019 not 2016 02, $100,000, footnote 13. In November 2016, No. 2016 18, Statement of Cash Flows No. 2016 18 January 1, 2018 December 31, 2018 2017, $110,000 $55,000, no In July 2017, 2017 11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception not no no 260 December 15, 2018. No. 2017 11 January 1, 2018. not not In June 2018, 2018 07, Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. 718 718 718 not 606, Revenue from Contracts with Customers December 15, 2018, No. 2018 17 April 1, 2018 not In June 2018, 2018 08, Not 958 not 958 December 15, 2018. Research and Development All research and development costs are expensed as incurred. Income Taxes The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Realization of deferred tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than not not not first not Cash and Cash Equivalents Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three Furniture and Equipment Furniture and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When furniture and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation is computed using the straight-line method over the estimated useful lives ranging from three five Furniture and equipment amounted to $216,000 $171,000 December 31, 2018 2017, $162,000 $160,000 December 31, 2018 2017, December 31, 2018 2017 $14,386 $25,956, The Company periodically evaluates the carrying value of long-lived assets to be held and used and, if necessary, records impairment losses when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-loved assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. For the years ended December 31, 2018 2017, no Fair Value Measurements The Company records financial assets and liabilities measured on a recurring and non-recurring basis as well as all non-financial assets and liabilities subject to fair value measurement at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. These fair value principles prioritize valuation inputs across three 1 2 3 Intangible Assets Intangible assets consist of intellectual property and software acquired. Intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the assets might not not During the year ended December 31, 2017, $461,715 December 31, 2017, zero December 31, 2017. No December 31, 2018. We determined the fair values of the Acueity intangibles using an income approach (Level 3 48.50%. 820, Fair Value Measurements Amortization of intangible assets is computed using the straight-line method over the estimated useful lives ranging from three ten Intangible assets amounted to $192,000 $234,000 December 31, 2018 2017, $93,000 $158,000 December 31, 2018 2017, December 31, 2018 2017 $29,811 $103,038, Financial Instruments with Characteristics of Both Liabilities and Equity During the year ended December 31, 2017, no December 31, 2018 2017. Share-Based Payments The Company follows the provisions of ASC Topic 718, Compensation - Stock Compensation 718” 718 The fair value of each option grant is estimated using the Black-Scholes option-pricing model, which requires assumptions regarding the expected volatility of the stock options, the expected life of the options, an expectation regarding future dividends on the Company’s common stock, and estimation of an appropriate risk-free interest rate. The Company’s expected common stock price volatility assumption is based upon the historical volatility of our stock price. The expected life assumption for stock options grants was based upon the simplified method provided for under ASC 718 10, ten one four zero no

Note 4 - Restricted Cash

Note 4 - Restricted Cash	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Restricted Assets Disclosure [Text Block]	NOTE 4: Our restricted cash balance of $110,000 $55,000 December 31, 2018 2017,

Note 5 - Prepaid Expenses

Note 5 - Prepaid Expenses	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Prepaid Expenses [Text Block]	NOTE 5: Prepaid expenses consisted of the following: December 31, December 31, 2018 2017 Prepaid insurance $ 160,576 $ 125,056 Prepaid research and development 218,090 Professional services 110,094 97,788 Retainer and security deposits 16,718 14,218 Other 4,355 13,882 Total prepaid expenses $ 509,833 $ 250,944

Note 6 - Research and Developme

Note 6 - Research and Development Tax Rebate Receivable	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Research and Development Tax Rebate Receivable [Text Block]	NOTE 6: On May 23, 2017, 1 2 $0.435 December 31, 2018 2017, $851,000 $824,000, $370,000 $358,000 December 31, 2018 2017, December 31, 2018, $518,000 $148,000 December 31, 2017.

Note 7 - Payroll Liabilities

Note 7 - Payroll Liabilities	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	NOTE 7 : PAYROLL LIABILITIES Payroll liabilities consisted of the following: December 31, 2018 December 31, 2017 Accrued bonus payable $ 697,995 $ 566,000 Accrued vacation 160,740 147,861 Accrued payroll liabilities 76,335 71,006 Total payroll liabilities $ 935,070 $ 784,867

Note 8 - Fair Value of Financia

Note 8 - Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 8 : FAIR VALUE OF FINANCIAL INSTRUMENTS There were no December 31, 2018 December 31, 2017. Warrants issued in the April 3, 2017, 9, not not 3 The following table summarizes the changes in the Company’s Level 3 December 31, 2017: Warrant liability Beginning balance $ Issuances of warrants 1,612,413 Warrant exercises (1,893,160 ) Change in fair value 280,747 Ending balance $ The Company’s intangible assets are classified within Level 3 3 There were no 1, 2 3 December 31, 2018 December 31, 2017.

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 9 : STOCKHOLDERS’ EQUITY The Company is authorized to issue a total of 185,000,000 175,000,000 $0.18 10,000,000 $0.001 750,000 $0.001 4,000 $0.001 25,000 $0.001 No December 31, 2018. On May 19, 2014, May 26, 2014, one one 1 15% 15% 2.0% 2 $15.00, $30.00 2017 On March 28, 2017, April 3, 2017. $4.4 $3.9 The offering included 55,333 $9.00 55,333 55,333 292 $12,000 292 389,111 389,111 44,167 44,167 $4.4 $11.25, five As of December 31, 2017, April 3, 2017 no Accounting Treatment The Company allocated the proceeds from the sale of the Class A and Class B units to the separate securities issued. The Company determined that, on the date of issuance, the warrants were not not The Company allocated the amount representing the fair value of the warrants at the date of issuance separately to the warrant liability and recorded the remaining proceeds as common stock, in the case of the Class A units, or as Series A convertible preferred stock, in the case of the Class B units. Due to the allocation of a portion of the proceeds to the warrants, the Series A convertible preferred stock contained a beneficial conversion feature upon issuance, which was recorded in the amount of $1,284,066 $1,284,066 $2,568,132 Exercise of 2017 On June 29, 2017, April 3, 2017. $3.12 $6.24 8:00 June 30, 2017. 250,000 125,000 1933, March 28, 2017, 45 not third 2017, no April 3, 2017, The following table summarizes the 2017 Shares Weighted Outstanding as of January 1, 2017 Warrants granted 488,611 $ 11.25 Warrants exercised (488,611 ) 3.12 Outstanding as of December 31, 2017 The Company estimated the fair value of the warrants using the Monte Carlo simulation (MCS) model, which is a type of income approach, where the current value of an asset is expressed as the sum of probable future cash flows across various scenarios and time frames discounted for risk and time. The significant assumptions included timing of future rounds of financing, timing and success rates of oncology clinical trials, and the probability of a merger and acquisition adjusted for a lack of marketability discount. The MCS model also included a full term and an early conversion scenario that were each weighted at 50% Inputs used in the valuation of the warrants at the issuance date of April 3, 2017 June 30, 2017, April 2017 2017 none December 31, 2017. Initial valuation Common stock price $9.00 Exercise price $11.25 Expected volatility 50% Dividend yield 0% Risk-free interest rate 0.79% - 1.88% Expected term (in years) 0.24 - 5 June 30, 2017 valuation Common stock price $6.00 Exercise price $3.12 Expected volatility 50% Dividend yield 0% Risk-free interest rate 0.79 - 1.88% Expected term (in years) 0.08 - 4.76 Conversion of Series A Convertible Preferred Stock During the year ended December 31, 2017, 292 389,111 111 December 31, 2017 2018, no October 2017 On October 26, 2017, October 30, 2017. $5.5 $4.9 The offering included 958,333 $5.28 83,333 $5.28 $5.5 December 2017 On December 20, 2017, December 20, 2017, 441,667 $3.24 $1.4 $1.2 Concurrently with the public offering the Company also commenced a private placement whereby it issued and sold Class A and Class B Warrants, exercisable for an aggregate of 883,333 $3.78 $3.78 six first None not no December 22, 2018, 2018 On May 9, 2018, 1 25,000 $1,000 one 284 On May 29, 2018, $0.001 25,000 On May 30, 2018, 13,624 13,624 3,869,216 one $4.048 “2018 $12.3 Series B Convertible Preferred Stock The terms and provisions of our Series B convertible preferred stock are: Conversion. first $1,000 $3.52 not 9.99% Fundamental Transactions. 50% 50% Dividends. Voting Rights. no Liquidation Preference . Redemption Rights. not not 2018 The terms and conditions of the warrants included in the 2018 Exercisability four The number of shares of common stock issuable upon exercise of the warrants is subject to adjustment in certain circumstances, including a stock split of, stock dividend on, or a subdivision, combination or recapitalization of the common stock. Upon the merger, consolidation, sale of substantially all of our assets, or other similar transaction, the holders of warrants shall, at the option of the company, be required to exercise the warrants immediately prior to the closing of the transaction, or such warrants shall automatically expire. Upon such exercise, the holders of warrants shall participate on the same basis as the holders of common stock in connection with the transaction. Cashless Exercise no not may Exercise Price one $4.048 not 4.99% may no 9.99% Transferability may may Exchange Listing not Rights as Stockholder not Redemption Rights may $0.18 $10.56 ten may not first Accounting Treatment The Company allocated the proceeds from the sale of the Series B convertible preferred stock and the warrants to purchase common stock to the separate securities issued. The Company allocated the amount representing the fair value of the warrants at the date of issuance to common stock based on the relative warrant fair value in the amount of $5,363,759, $4,782,100 $11,479,308, $4,782,100, $5,363,759, $1,333,449. $11,479,308 Outstanding Warrants As of December 31, 2018, 3,875,699 Outstanding Warrants to Purchase Shares Exercise Price Expiration Date 2014 public offering 6,483 $ 540.00 January 29, 2019 2018 warrants 3,869,216 4.05 May 30, 2022 3,875,699 Conversion of Series B Convertible Preferred Stock During the year ended December 31, 2018, 11,245 3,194,600 284

Note 10 - Net Loss Per Share

Note 10 - Net Loss Per Share	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 1 0 : NET LOSS PER SHARE The Company accounts for and discloses net income (loss) per common share in accordance with Accounting Standards Codification ("ASC") Topic 260, Earnings Per Share The following table summarizes the Company’s calculation of net loss per common share: Year Ended December 31, 2018 2017 Numerator Net loss $ (11,404,934 ) $ (8,122,581 ) Deemed dividend attributable to preferred stock (11,479,308 ) (2,568,132 ) Net loss attributable to common shareholders $ (22,884,242 ) $ (10,690,713 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 4,157,746 974,773 Net loss per share of common stock, basic and diluted: $ (5.50 ) $ (10.97 ) The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share, because including them would be anti-dilutive: Year Ended December 31, 2018 2017 Options to purchase common stock 487,941 117,301 Series A convertible preferred stock 55,835 Series B convertible preferred stock 774,983 Warrants to purchase common stock 3,054,481 202,063 4,317,405 375,199

Note 11 - Income Taxes

Note 11 - Income Taxes	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 1 1 : INCOME TAXES The Company accounts for income taxes using the asset and liability method, under which deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not On December 22, 2017, 2017 “2017 2017 35% 21%, 740, Accounting for Income Taxes During the year ended December 31, 2017, $1.9 2017 35% 21%, The Company did not December 31, 2018 2017, As of December 31, 2018 2017 Expected federal income tax benefit $ (2,395,036 ) $ (2,761,678 ) Stock compensation 169,957 197,336 Other permanent items 1,616 2,668 Effect of change in valuation allowance 2,223,463 (15,344,015 ) Prior year true-up (126,031 ) Tax rate change 1,912,427 Effect of NOL limitation 16,119,293 Actual federal income tax benefit $ $ The components of net deferred tax assets and liabilities are as follows: Year Ended December 31, 2018 2017 Deferred tax assets Obsolete inventory $ 21,881 $ 21,881 Accrued vacation 33,755 31,051 Accrued bonuses 99,666 Stock-based compensation 968,170 620,789 Basis difference in fixed assets 33,241 33,241 Intangible assets, net 572,687 634,521 Contribution, carryforward 707 677 Net operating loss carryforwards 2,588,401 747,589 Capital loss carryforward 1,027,111 1,027,111 Valuation allowance (5,312,769 ) (3,089,306 ) Deferred tax asset $ 32,850 $ 27,554 Deferred tax liabilities Other $ (32,850 ) $ (27,554 ) Net deferred tax asset $ $ Based on an assessment of all available evidence including, but not not not may may 382. three 50 may 382 The Company has incurred net operating losses from inception. At December 31, 2018, $58.2 May 2018 October 2017, 382. December 31, 2018, 12.3 December 31, 2017 2029 2038, 2018 not $5.3 $3.1 December 31, 2018 2017, $2.2 2017 2018 $15.5 2016 2017. The Company files income tax returns in the U.S. The Company is subject to tax examinations for the 2012 no not 12 not

Note 12 - Concentration of Cred

Note 12 - Concentration of Credit Risk	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 1 2 : CONCENTRATION OF CREDIT RISK Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. December 31, 2018 2017, $10,052,914 $6,967,469

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 1 3 : COMMITMENTS AND CONTINGENCIES Lease Commitments On November 1, 2018, $3,660 22 are $73,200 $43,920 $29,280 2019 2020, The total rent expense for the years ended December 31, 2018 2017, $31,457 $33,285, On October 30, 2018, 36 $42,228, $14,904, $14,904 $12,420 2019, 2020 2021, Litigation and Contingencies On October 10, 2013, Cook v. Atossa Genetics, Inc., et al. No. 2:13 01836 November 2012 11 12 2 15, 10 20A 10b 5 November 8, 2012 October 4, 2013, unspecific amount. March 23, 2018, $3.5 July 20, 2018 We are subject to other legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should not

Note 14 - Stock Based Compensat

Note 14 - Stock Based Compensation	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 1 4 : STOCK BASED COMPENSATION Stock Option and Incentive Plan On September 28, 2010, 2010 “2010 may 2010 September 2020. No may 2010 10 5,556 2010 May 18, 2016, 11,111 2010 May 9, 2017, 125,000 2010 April 12, 2018, 500,000 2010 The following table presents the automatic additions to the 2010 2010 January 1, Number of 2012 2,502 2013 2,871 2014 4,128 2015 5,463 2016 7,257 2017 12,623 2018 106,076 Total additional shares 140,920 The Company granted options to purchase 611,668 143,027 December 31, 2018 2017, 2018 2017 $2.02 $4.80, 3,575 2010 December 31, 2018, 2010 233,862 2010 January 1, 2019. Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $1,053,496 $786,550 December 31, 2018 2017, Year Ended December 31, 201 8 201 7 General and administrative $ 809,110 $ 621,668 Research and development 244,386 164,882 Total stock compensation expense $ 1,053,496 $ 786,550 The fair value of stock options granted for the years ended December 31, 2018 2017, Year ended December 31, 201 8 201 7 Risk free interest rate 2.47% - 2.71% 1.86% - 2.04% Expected term (in years) 5.24 - 5.57 5.32 - 6.36 Dividend yield -% -% Expected volatility 108.81% - 126.43% 112.86% - 114.19 Options issued and outstanding as of December 31, 2018, Number of Weighted- Weighted- Aggregate Outstanding as of January 1, 2018 172,510 $ 49.27 $ Granted 611,668 2.39 Forfeited (795 ) 562.55 Outstanding as of December 31, 2018 783,383 12.14 9.17 $ Exercisable as of December 31, 2018 317,042 24.39 8.97 $ Vested and expected to vest 783,383 12.14 9.17 $ At December 31, 2018, 466,341 $1,152,367. 1.45 Executive Option Grants Classified as Liabilities ( "2018 On June 27, 2018, 2,300,000 700,000 2010 2010 January 13, 2019, 2018 The Liability Grants were exercisable for shares of common stock at an exercise price of $2.38 ten not The Liability Grants were subject to vesting requirements. Twenty- five 50% two 25% December 31, 2018, December 31, 2018, 1,125,000 $857,673. 1.5 Compensation costs associated with the Liability Grants were initially recognized, based on the grant-date fair values of these options, over the requisite or vesting period for time-based options or when it is probable the performance criteria were achieved for options that vest based on performance. Compensation cost was remeasured each period based on the market value of our underlying stock until award vesting or settlement. For the year ended December 31, 2018, $1,410,025, Year Ended December 31, 2018 General and administrative $ 869,515 Research and development 540,510 Total stock compensation expense $ 1,410,025 The fair value of liability options granted for the year ended December 31, 2018, Year Ended December 31 , 2018 Risk free interest rate 2.51 - 2.94% Expected term (in years) 4.5 - 5.0 Stock price $1.02 - $2.38 Dividend yield % Expected volatility 122.0 - 125.0% Refer to footnote 16

Note 15 - Restatement to Previo

Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Reclassifications [Text Block]	NOTE 15: The Company has corrected an inadvertent error in the calculation of the deemed dividend on Series B convertible preferred stock in the financial statements for the three six June 30, 2018 10 August 13, 2018 ( 10 May 2018 10 not not three six June 30, 2018 $4,782,100, $11,479,308. not In accordance with applicable generally accepted accounting principles, the Company has calculated and recognized adjustments accordingly. The following table shows the effect of the restatement on certain line items within the Company’s Condensed Consolidated Statement of Operations for the three six June 30, 2018: For the Three Months Ended For the Six Months Ended Previously Reported Restated Previously Reported Restated Deemed dividend attributable to preferred stock $ (4,782,100 ) $ (11,479,308 ) $ (4,782,100 ) $ (11,479,308 ) Net loss applicable to common stockholders $ (8,924,677 ) $ (15,621,885 ) $ (10,799,059 ) $ (17,496,267 ) Loss per common share -basic and diluted $ (2.90 ) $ (5.08 ) $ (3.77 ) $ (6.11 ) The following table shows the effect of the restatement on certain line items within the Company’s Condensed Consolidated Statement of Stockholders’ Equity for the six June 30, 2018: Preferred Stock Additional Paid-in Capital Common Stock Additional Paid-in Capital Previously Reported Restated Previously Reported Restated Issuance of Series B convertible preferred stock, net of issuance costs $ 12,290,537 $ 6,926,778 $ 0 $ 5,363,759 Deemed Dividend on Series B convertible preferred stock $ 4,782,100 $ 11,479,308 $ (4,782,100 ) $ (11,479,308 ) Conversion of Series B convertible preferred stock to common stock $ (7,056,421 ) $ (7,821,992 ) $ 6,656,442 $ 7,422,013

Note 16 - Subsequent Events

Note 16 - Subsequent Events	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 16 : SUBSEQUENT EVENTS Stock Option and Incentive Plan June 27, 2018, 2,300,000 700,000 “2018 2018 2018 not On January 13, 2019, 2018 no no January 13, 2019, 2,300,000 800,000 “2019 2019 $1.36 not January 13, 2019, 2019 2019 not 2018 2019 not 3,575 December 31, 2018, 2019 The above actions were unanimously approved by the disinterested members of the Board of Directors. The above actions are intended to eliminate the Company’s potential liability associated with the Net Cash Exercise Provision of the liability options, and to allow the stockholders of the Company the opportunity to vote on the Amended Plan, which includes shares issuable upon exercise of the 2019 Warrant Exercises In March 2019, $11.3 May 30, 2018. 2.8 2.8

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation: The accompanying consolidated financial statements have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the financial statements of Atossa Genetics Inc. and its wholly-owned subsidiaries. All significant intercompany account balances and transactions have been eliminated in consolidation. On April 20, 2018, 1 12 12 one $0.18 not April 20, 2018.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements: In February 2016, No. 2016 02, Lease Accounting Topic 842. December 15, 2018 two one one January 1, 2019 not 2016 02, $100,000, footnote 13. In November 2016, No. 2016 18, Statement of Cash Flows No. 2016 18 January 1, 2018 December 31, 2018 2017, $110,000 $55,000, no In July 2017, 2017 11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception not no no 260 December 15, 2018. No. 2017 11 January 1, 2018. not not In June 2018, 2018 07, Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. 718 718 718 not 606, Revenue from Contracts with Customers December 15, 2018, No. 2018 17 April 1, 2018 not In June 2018, 2018 08, Not 958 not 958 December 15, 2018.
Research and Development Expense, Policy [Policy Text Block]	Research and Development All research and development costs are expensed as incurred.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Realization of deferred tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than not not not first not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three
Property, Plant and Equipment, Policy [Policy Text Block]	Furniture and Equipment Furniture and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When furniture and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation is computed using the straight-line method over the estimated useful lives ranging from three five Furniture and equipment amounted to $216,000 $171,000 December 31, 2018 2017, $162,000 $160,000 December 31, 2018 2017, December 31, 2018 2017 $14,386 $25,956, The Company periodically evaluates the carrying value of long-lived assets to be held and used and, if necessary, records impairment losses when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-loved assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. For the years ended December 31, 2018 2017, no
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The Company records financial assets and liabilities measured on a recurring and non-recurring basis as well as all non-financial assets and liabilities subject to fair value measurement at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. These fair value principles prioritize valuation inputs across three 1 2 3
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Intangible Assets Intangible assets consist of intellectual property and software acquired. Intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the assets might not not During the year ended December 31, 2017, $461,715 December 31, 2017, zero December 31, 2017. No December 31, 2018. We determined the fair values of the Acueity intangibles using an income approach (Level 3 48.50%. 820, Fair Value Measurements Amortization of intangible assets is computed using the straight-line method over the estimated useful lives ranging from three ten Intangible assets amounted to $192,000 $234,000 December 31, 2018 2017, $93,000 $158,000 December 31, 2018 2017, December 31, 2018 2017 $29,811 $103,038,
Financial Instruments with Characteristics of Both Liabilities and Equity, Policy [Policy Text Block]	Financial Instruments with Characteristics of Both Liabilities and Equity During the year ended December 31, 2017, no December 31, 2018 2017.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-Based Payments The Company follows the provisions of ASC Topic 718, Compensation - Stock Compensation 718” 718 The fair value of each option grant is estimated using the Black-Scholes option-pricing model, which requires assumptions regarding the expected volatility of the stock options, the expected life of the options, an expectation regarding future dividends on the Company’s common stock, and estimation of an appropriate risk-free interest rate. The Company’s expected common stock price volatility assumption is based upon the historical volatility of our stock price. The expected life assumption for stock options grants was based upon the simplified method provided for under ASC 718 10, ten one four zero no

Note 5 - Prepaid Expenses (Tabl

Note 5 - Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	December 31, December 31, 2018 2017 Prepaid insurance $ 160,576 $ 125,056 Prepaid research and development 218,090 Professional services 110,094 97,788 Retainer and security deposits 16,718 14,218 Other 4,355 13,882 Total prepaid expenses $ 509,833 $ 250,944

Note 7 - Payroll Liabilities (T

Note 7 - Payroll Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, 2018 December 31, 2017 Accrued bonus payable $ 697,995 $ 566,000 Accrued vacation 160,740 147,861 Accrued payroll liabilities 76,335 71,006 Total payroll liabilities $ 935,070 $ 784,867

Note 8 - Fair Value of Financ_2

Note 8 - Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Warrant liability Beginning balance $ Issuances of warrants 1,612,413 Warrant exercises (1,893,160 ) Change in fair value 280,747 Ending balance $

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Warrants Activity [Table Text Block]	Shares Weighted Outstanding as of January 1, 2017 Warrants granted 488,611 $ 11.25 Warrants exercised (488,611 ) 3.12 Outstanding as of December 31, 2017
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Outstanding Warrants to Purchase Shares Exercise Price Expiration Date 2014 public offering 6,483 $ 540.00 January 29, 2019 2018 warrants 3,869,216 4.05 May 30, 2022 3,875,699
Warrant [Member]
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Initial valuation Common stock price $9.00 Exercise price $11.25 Expected volatility 50% Dividend yield 0% Risk-free interest rate 0.79% - 1.88% Expected term (in years) 0.24 - 5 June 30, 2017 valuation Common stock price $6.00 Exercise price $3.12 Expected volatility 50% Dividend yield 0% Risk-free interest rate 0.79 - 1.88% Expected term (in years) 0.08 - 4.76

Note 10 - Net Loss Per Share (T

Note 10 - Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, 2018 2017 Numerator Net loss $ (11,404,934 ) $ (8,122,581 ) Deemed dividend attributable to preferred stock (11,479,308 ) (2,568,132 ) Net loss attributable to common shareholders $ (22,884,242 ) $ (10,690,713 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 4,157,746 974,773 Net loss per share of common stock, basic and diluted: $ (5.50 ) $ (10.97 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2018 2017 Options to purchase common stock 487,941 117,301 Series A convertible preferred stock 55,835 Series B convertible preferred stock 774,983 Warrants to purchase common stock 3,054,481 202,063 4,317,405 375,199

Note 11 - Income Taxes (Tables)

Note 11 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	As of December 31, 2018 2017 Expected federal income tax benefit $ (2,395,036 ) $ (2,761,678 ) Stock compensation 169,957 197,336 Other permanent items 1,616 2,668 Effect of change in valuation allowance 2,223,463 (15,344,015 ) Prior year true-up (126,031 ) Tax rate change 1,912,427 Effect of NOL limitation 16,119,293 Actual federal income tax benefit $ $
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Year Ended December 31, 2018 2017 Deferred tax assets Obsolete inventory $ 21,881 $ 21,881 Accrued vacation 33,755 31,051 Accrued bonuses 99,666 Stock-based compensation 968,170 620,789 Basis difference in fixed assets 33,241 33,241 Intangible assets, net 572,687 634,521 Contribution, carryforward 707 677 Net operating loss carryforwards 2,588,401 747,589 Capital loss carryforward 1,027,111 1,027,111 Valuation allowance (5,312,769 ) (3,089,306 ) Deferred tax asset $ 32,850 $ 27,554 Deferred tax liabilities Other $ (32,850 ) $ (27,554 ) Net deferred tax asset $ $

Note 14 - Stock Based Compens_2

Note 14 - Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	January 1, Number of 2012 2,502 2013 2,871 2014 4,128 2015 5,463 2016 7,257 2017 12,623 2018 106,076 Total additional shares 140,920
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year ended December 31, 201 8 201 7 Risk free interest rate 2.47% - 2.71% 1.86% - 2.04% Expected term (in years) 5.24 - 5.57 5.32 - 6.36 Dividend yield -% -% Expected volatility 108.81% - 126.43% 112.86% - 114.19
Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Weighted- Weighted- Aggregate Outstanding as of January 1, 2018 172,510 $ 49.27 $ Granted 611,668 2.39 Forfeited (795 ) 562.55 Outstanding as of December 31, 2018 783,383 12.14 9.17 $ Exercisable as of December 31, 2018 317,042 24.39 8.97 $ Vested and expected to vest 783,383 12.14 9.17 $
Liability Options [Member]
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Year Ended December 31, 2018 General and administrative $ 869,515 Research and development 540,510 Total stock compensation expense $ 1,410,025
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31 , 2018 Risk free interest rate 2.51 - 2.94% Expected term (in years) 4.5 - 5.0 Stock price $1.02 - $2.38 Dividend yield % Expected volatility 122.0 - 125.0%
Employee Stock Option [Member]
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Year Ended December 31, 201 8 201 7 General and administrative $ 809,110 $ 621,668 Research and development 244,386 164,882 Total stock compensation expense $ 1,053,496 $ 786,550

Note 15 - Restatement to Prev_2

Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	For the Three Months Ended For the Six Months Ended Previously Reported Restated Previously Reported Restated Deemed dividend attributable to preferred stock $ (4,782,100 ) $ (11,479,308 ) $ (4,782,100 ) $ (11,479,308 ) Net loss applicable to common stockholders $ (8,924,677 ) $ (15,621,885 ) $ (10,799,059 ) $ (17,496,267 ) Loss per common share -basic and diluted $ (2.90 ) $ (5.08 ) $ (3.77 ) $ (6.11 ) Preferred Stock Additional Paid-in Capital Common Stock Additional Paid-in Capital Previously Reported Restated Previously Reported Restated Issuance of Series B convertible preferred stock, net of issuance costs $ 12,290,537 $ 6,926,778 $ 0 $ 5,363,759 Deemed Dividend on Series B convertible preferred stock $ 4,782,100 $ 11,479,308 $ (4,782,100 ) $ (11,479,308 ) Conversion of Series B convertible preferred stock to common stock $ (7,056,421 ) $ (7,821,992 ) $ 6,656,442 $ 7,422,013

Note 2 - Liquidity and Capita_2

Note 2 - Liquidity and Capital Resources (Details Textual) - USD ($)	1 Months Ended		12 Months Ended
	Mar. 25, 2019	Mar. 24, 2019	Dec. 31, 2018	Dec. 31, 2017
Net Income (Loss) Attributable to Parent, Total			$ (11,404,934)	$ (8,122,581)
Net Cash Provided by (Used in) Operating Activities, Total			(8,961,621)	(6,593,950)
Cash and Cash Equivalents, at Carrying Value, Ending Balance			10,380,493	7,217,469
Working Capital			8,600,000
Proceeds from Warrant Exercises				$ 749,233
Subsequent Event [Member]
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 19,300,000
Proceeds from Warrant Exercises	$ 11,300,000	$ 11,300,000

Note 3 - Summary of Accountin_2

Note 3 - Summary of Accounting Policies (Details Textual)	Apr. 20, 2018	Dec. 31, 2018USD ($)$ / shares	Dec. 31, 2017USD ($)$ / shares
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.18	$ 0.18
Restricted Cash and Cash Equivalents, Total		$ 110,000	$ 55,000
Property, Plant and Equipment, Gross, Ending Balance		216,000	171,000
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance		162,000	160,000
Depreciation, Total		14,386	25,956
Impairment of Long-Lived Assets Held-for-use		0	0
Impairment of Intangible Assets (Excluding Goodwill), Total		0	461,715
Intangible Assets, Net (Excluding Goodwill), Total		$ 192,000	234,000
Intangible Asset, Measurement Input		0.485
Finite-Lived Intangible Assets, Accumulated Amortization		$ 93,000	158,000
Amortization of Intangible Assets, Total		29,811	103,038
Warrant Liabilities		$ 0	0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%
Acueity intangible Assets [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total			461,715
Intangible Assets, Net (Excluding Goodwill), Total			$ 0
Minimum [Member]
Property, Plant and Equipment, Useful Life		3 years
Finite-Lived Intangible Asset, Useful Life		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Vesting Term		1 year
Maximum [Member]
Property, Plant and Equipment, Useful Life		5 years
Finite-Lived Intangible Asset, Useful Life		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Vesting Term		4 years
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	12

Note 4 - Restricted Cash (Detai

Note 4 - Restricted Cash (Details Textual) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Restricted Cash and Cash Equivalents, Total	$ 110,000	$ 55,000

Note 5 - Prepaid Expenses - Sch

Note 5 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Prepaid insurance	$ 160,576	$ 125,056
Prepaid research and development	218,090
Professional services	110,094	97,788
Retainer and security deposits	16,718	14,218
Other	4,355	13,882
Total prepaid expenses	$ 509,833	$ 250,944

Note 6 - Research and Develop_2

Note 6 - Research and Development Tax Rebate Receivable (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	May 23, 2017
Research and Development Expense, Total	$ 4,209,981	$ 2,328,087
Increase (Decrease) in Research and Development Tax Rebate Receivable	159,821	358,277
Research and Development Tax Rebate Receivable	518,098	358,277
Atossa Genetics AUS Pty Ltd [Member]
Research and Development Cash Rebate per Dollar			$ 0.435
Research and Development Expense, Total	851,000	824,000
Increase (Decrease) in Research and Development Tax Rebate Receivable	370,000	358,000
Research and Development Tax Rebate Receivable	$ 518,000	$ 148,000

Note 7 - Payroll Liabilities -

Note 7 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Accrued bonus payable	$ 697,995	$ 566,000
Accrued vacation	160,740	147,861
Accrued payroll liabilities	76,335	71,006
Total payroll liabilities	$ 935,070	$ 784,867

Note 8 - Fair Value of Financ_3

Note 8 - Fair Value of Financial Instruments (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Measurements, Recurring [Member]
Assets, Fair Value Disclosure	$ 0	$ 0

Note 8 - Fair Value of Financ_4

Note 8 - Fair Value of Financial Instruments - Changes in Level 3 Warrant Liability (Details) - Warrant Liability [Member]	12 Months Ended
	Dec. 31, 2017USD ($)
Beginning balance
Issuances of warrants	1,612,413
Warrant exercises	(1,893,160)
Change in fair value	280,747
Ending balance

Note 9 - Stockholders' Equity_2

Note 9 - Stockholders' Equity (Details Textual)	May 30, 2018USD ($)$ / sharesshares	Dec. 20, 2017USD ($)$ / sharesshares	Oct. 26, 2017USD ($)$ / sharesshares	Jun. 29, 2017$ / sharesshares	Apr. 03, 2017USD ($)$ / shares$ / itemshares	Jun. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	May 29, 2018$ / sharesshares	May 09, 2018$ / itemshares	Sep. 30, 2017shares	Dec. 31, 2016$ / sharesshares	May 19, 2014$ / sharesshares
Number of Shares Authorized to Issue								185,000,000
Common Stock, Shares Authorized								175,000,000	175,000,000
Common Stock, Par or Stated Value Per Share | $ / shares								$ 0.18	$ 0.18
Preferred Stock, Shares Authorized								10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share | $ / shares								$ 0.001	$ 0.001
Stockholder Rights Agreement, Number of Preferred Stock Right Distributed for Each Share of Common Stock														1
Stockholder Rights Agreement, Acquiring Person, Percentage of Ownership														15.00%
Stockholder Rights Agreement, Acquiring Person, Additional Percentage of Ownership														2.00%
Stockholder Rights Agreement, Initial Exercise Price of Each Right | $ / shares														$ 15
Stockholder Rights Agreement, Share Price | $ / shares														$ 30
Stock Issued During Period, Shares, New Issues				125,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares									$ 0				$ 0
Preferred Stock, Deemed Dividend | $						$ 11,479,308	$ 11,479,308	$ 11,479,308	$ 2,568,132
Lock-up Period Extension				45 days
Class of Warrant or Right, Outstanding								3,875,699	0				0
Proceeds from Issuance of Stock units | $									$ 3,871,636
Consummate a Business Combination, Percentage of Acquired Outstanding Shares								50.00%
Consummate a Business Combination, Percentage of Aggregate Ordinary Voting Power								50.00%
Conversion of Series A Convertible Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Converted									292
Stock Issued During Period, Shares, Conversion of Convertible Securities									389,111
Convertible Preferred Stock, Shares Issued upon Conversion									111
Conversion of Series B Convertible Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Converted								11,245
Convertible Preferred Stock, Shares Issued upon Conversion								284
Conversion of Stock, Shares Issued								3,194,600
The 2017 Public Offering Class B Units Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 3.12
Class of Warrant or Right Cancelled				250,000
Class of Warrant or Right, Outstanding									0			0
The 2017 Public Offering Class B Units Warrants [Member] | Weighted Average [Member]
Share Price | $ / shares				$ 6.24
The 2018 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 4.048
Warrants and Rights Outstanding, Term								4 years
Class of Warrant or Right, Outstanding								3,869,216
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right								1
Warrants Exercisable, Ownership Percentage of Company’s Shares Allowed								4.99%
Common Stock, Convertible, Ownership Percentage of Company’s Shares Allowed								9.99%
Warrants and Rights Outstanding, Redemption Price | $ / shares								$ 0.18
Warrants and Rights Outstanding, Redeemable, Volume-weighted-average-price of Our Common Stock | $ / shares								$ 10.56
Warrants and Rights, Redemption Rights, Consecutive Trading Days								10
The 2017 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total | $					$ 4,400,000
Proceeds from Issuance or Sale of Equity, Net | $					$ 3,900,000
Stock Issued During Period, Shares, New Issues					55,333
Adjustments to Additional Paid in Capital, Beneficial Conversion Feature on Preferred Stock | $					$ 1,284,066
The 2017 Public Offering [Member] | The 2017 Public Offering Class A Units Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					55,333
The 2017 Public Offering [Member] | The 2017 Public Offering Class B Units Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					389,111
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues			83,333		44,167
Shares Issued, Price Per Share | $ / shares			$ 5.28
Over-Allotment Option [Member] | The 2017 Public Offering Over-allotment Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					44,167
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 11.25
Warrants and Rights Outstanding, Term					5 years
October 2017 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Net | $			$ 4,900,000
Stock Issued During Period, Shares, New Issues			958,333
Proceeds from Issuance of Common Stock | $			$ 5,500,000
Shares Issued, Price Per Share | $ / shares			$ 5.28
December 2017 Public Offering and Private Placement [Member]
Proceeds from Issuance or Sale of Equity, Net | $		$ 1,200,000
Stock Issued During Period, Shares, New Issues		441,667
Proceeds from Issuance of Common Stock | $		$ 1,400,000
Shares Issued, Price Per Share | $ / shares		$ 3.24
December 2017 Public Offering and Private Placement [Member] | Class A and Class B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		883,333
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 3.78
Warrants and Rights Outstanding, Term		1 year
Class of Warrant or Right, Exercisable Period		180 days
The 2018 Subscription Rights Offering [Member]
Number of Units Sold	13,624
Purchase Price of Unit | $ / item											1,000
Adjustments to Additional Paid in Capital, Beneficial Conversion Feature on Preferred Stock | $								$ 4,782,100
Preferred Stock, Deemed Dividend | $								11,479,308
Number of Units Authorized to Purchase, Maximum											25,000
Number of Series B Convertible Preferred Stock and Warrant in Each Unit											1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right											284
Proceeds from Issuance of Stock units | $	$ 12,300,000
Payments of Stock Issuance Costs | $								1,333,449
The 2018 Subscription Rights Offering [Member] | The 2018 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.048
Class of Warrant or Right, Outstanding	3,869,216
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
Warrants Allocated to Common Stock , Net of Issuance Cost | $								$ 5,363,759
Series A Junior Participating Preferred Stock [Member]
Preferred Stock, Shares Authorized								750,000
Preferred Stock, Par or Stated Value Per Share | $ / shares								$ 0.001
Preferred Stock, Shares Issued, Total								0
Preferred Stock, Shares Outstanding, Ending Balance								0
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized								4,000	4,000
Preferred Stock, Par or Stated Value Per Share | $ / shares								$ 0.001	$ 0.001
Preferred Stock, Shares Issued, Total								0
Preferred Stock, Deemed Dividend | $					$ 2,568,132
Preferred Stock, Shares Outstanding, Ending Balance								0	0
Series A Convertible Preferred Stock [Member] | The 2017 Public Offering [Member]
Stock Issued During Period, Shares, New Issues					292
Convertible Preferred Stock, Shares Issuable					389,111
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized								25,000	0	25,000
Preferred Stock, Par or Stated Value Per Share | $ / shares								$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Shares Issued, Total								2,379	0
Preferred Stock, Shares Outstanding, Ending Balance								2,379	0
Stated Value per Share | $ / shares								1,000
Preferred Stock, Convertible, Conversion Price | $ / shares								$ 3.52
Preferred Stock, Convertible, Ownership Percentage of Company’s Shares Allowed								9.99%
Series B Convertible Preferred Stock [Member] | The 2018 Subscription Rights Offering [Member]
Stock Issued During Period, Shares, New Issues	13,624
Class A Units [Member] | The 2017 Public Offering [Member]
Number of Units Sold					55,333
Purchase Price of Unit | $ / item					9
Class B Units [Member] | The 2017 Public Offering [Member]
Number of Units Sold					292
Purchase Price of Unit | $ / item					12,000

Note 9 - Stockholders' Equity -

Note 9 - Stockholders' Equity - 2017 Liability Warrant Activity (Details)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Outstanding as of January 1, 2017 (in shares) | shares	0
Outstanding as of January 1, 2017 (in dollars per share) | $ / shares	$ 0
Warrants granted (in shares) | shares	488,611
Warrants granted, exercise price (in dollars per share) | $ / shares	$ 11.25
Warrants exercised (in shares) | shares	(488,611)
Warrants exercised, , exercise price (in dollars per share) | $ / shares	$ 3.12
Outstanding as of December 31, 2017 (in shares) | shares	0
Outstanding as of December 31, 2017 (in dollars per share) | $ / shares	$ 0

Note 9 - Stockholders' Equity_3

Note 9 - Stockholders' Equity - Inputs Used in Valuation of Warrants (Details)	Jun. 30, 2017	Apr. 03, 2017
Measurement Input, Share Price [Member]
Inputs	6	9
Measurement Input, Exercise Price [Member]
Inputs	3.12	11.25
Measurement Input, Price Volatility [Member]
Inputs	0.5	0.5
Measurement Input, Expected Dividend Rate [Member]
Inputs	0	0
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Inputs	0.0079	0.0079
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Inputs	0.0188	0.0188
Measurement Input, Expected Term [Member] | Minimum [Member]
Inputs	0.08	0.24
Measurement Input, Expected Term [Member] | Maximum [Member]
Inputs	4.76	5

Note 9 - Stockholders' Equity_4

Note 9 - Stockholders' Equity - Schedule of Warrants Outstanding (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Outstanding Warrants to Purchase Shares (in shares)	3,875,699	0	0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0	$ 0
Class of Warrant or Right, Exercise Price of Warrants or Rights
The 2014 Public Offering [Member]
Outstanding Warrants to Purchase Shares (in shares)	6,483
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 540
Class of Warrant or Right, Exercise Price of Warrants or Rights	January 29, 2019
The 2018 Warrants [Member]
Outstanding Warrants to Purchase Shares (in shares)	3,869,216
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 4.048
Class of Warrant or Right, Exercise Price of Warrants or Rights	May 30, 2022

Note 10 - Net Loss Per Share -

Note 10 - Net Loss Per Share - Schedule of Earnings Per Share (Details) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Net loss			$ (11,404,934)	$ (8,122,581)
Deemed dividend attributable to preferred stock	$ (11,479,308)	$ (11,479,308)	(11,479,308)	(2,568,132)
Net loss attributable to common shareholders	$ (15,621,885)	$ (17,496,267)	$ (22,884,242)	$ (10,690,713)
Weighted average shares outstanding - basic and diluted (in shares)			4,157,746	974,773
Loss per common share -basic and diluted (in dollars per share)	$ (5.08)	$ (6.11)	$ (5.50)	$ (10.97)

Note 10 - Net Loss Per Share _2

Note 10 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of potential common shares excluded (in shares)	4,317,405	375,199
Employee Stock Option [Member]
Number of potential common shares excluded (in shares)	487,941	117,301
Series A Convertible Preferred Stock [Member]
Number of potential common shares excluded (in shares)		55,835
Series B Convertible Preferred Stock [Member]
Number of potential common shares excluded (in shares)	774,983
Warrant [Member]
Number of potential common shares excluded (in shares)	3,054,481	202,063

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Reduction in Deferred Tax Assets		$ 1,900,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	35.00%
Income Tax Expense (Benefit), Total	$ 0	$ 0
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	12,300,000
Deferred Tax Assets, Valuation Allowance, Total	5,312,769	3,089,306
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	2,200,000	(15,500,000)
Unrecognized Tax Benefits, Ending Balance	0	0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0	$ 0
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	$ 58,200,000
Open Tax Year	2012 2013 2014 2015 2016 2017 2018
Domestic Tax Authority [Member] | Earliest Tax Year [Member]
Operating Loss Carryforwards, Expiration Year	2029
Domestic Tax Authority [Member] | Latest Tax Year [Member]
Operating Loss Carryforwards, Expiration Year	2038

Note 11 - Income Taxes - Effect

Note 11 - Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Expected federal income tax benefit	$ (2,395,036)	$ (2,761,678)
Stock compensation	169,957	197,336
Other permanent items	1,616	2,668
Effect of change in valuation allowance	2,223,463	(15,344,015)
Prior year true-up		(126,031)
Tax rate change		1,912,427
Effect of NOL limitation		16,119,293
Actual federal income tax benefit	$ 0	$ 0

Note 11 - Income Taxes - Compon

Note 11 - Income Taxes - Components of Net Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Obsolete inventory	$ 21,881	$ 21,881
Deferred tax assets, accrued vacation	33,755	31,051
Accrued bonuses	99,666
Stock-based compensation	968,170	620,789
Basis difference in fixed assets	33,241	33,241
Intangible assets, net	572,687	634,521
Contribution, carryforward	707	677
Net operating loss carryforwards	2,588,401	747,589
Capital loss carryforward	1,027,111	1,027,111
Valuation allowance	(5,312,769)	(3,089,306)
Deferred tax asset	32,850	27,554
Other	(32,850)	(27,554)
Net deferred tax asset	$ 0	$ 0

Note 12 - Concentration of Cr_2

Note 12 - Concentration of Credit Risk (Details Textual) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Cash, Uninsured Amount	$ 10,052,914	$ 6,967,469

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies (Details Textual) - USD ($)	Nov. 01, 2018	Mar. 23, 2018	Dec. 31, 2018	Dec. 31, 2017	Oct. 30, 2018
Operating Lease, Lessee, Monthly Rent Expense	$ 3,660
Lessee, Operating Lease, Term of Contract	1 year 300 days
Operating Leases, Future Minimum Payments Due, Total			$ 73,200
Operating Leases, Future Minimum Payments Due, Next Twelve Months			43,920
Operating Leases, Future Minimum Payments, Due in Two Years			29,280
Operating Leases, Rent Expense, Net, Total			31,457	$ 33,285
Loss Contingency, Damages Paid, Value		$ 3,500,000
Lease for Copier System [Member]
Lessee, Operating Lease, Term of Contract					3 years
Operating Leases, Future Minimum Payments Due, Total			42,228
Operating Leases, Future Minimum Payments Due, Next Twelve Months			14,904
Operating Leases, Future Minimum Payments, Due in Two Years			14,904
Operating Leases, Future Minimum Payments, Due in Three Years			$ 12,420

Note 14 - Stock Based Compens_3

Note 14 - Stock Based Compensation (Details Textual) - USD ($)	Jan. 01, 2019	Jun. 27, 2018	Apr. 12, 2018	May 09, 2017	May 18, 2016	Sep. 28, 2010	Dec. 31, 2018	Dec. 31, 2017
Allocated Share-based Compensation Expense, Total							$ 1,053,496	$ 786,550
Liability Options [Member]
Allocated Share-based Compensation Expense, Total							$ 1,410,025
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance							1,125,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options							$ 857,673
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition							1 year 182 days
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 2.38
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Liability Options [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Liability Options [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		2 years
Liability Options [Member] | Share-based Compensation Award, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Liability Options [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		2,300,000
Liability Options [Member] | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		700,000
The 2010 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Period for Granting Shares						10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							611,668
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price							$ 2.39
The 2010 Stock Option and Incentive Plan [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	233,862
The 2010 Stock Option and Incentive Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						5,556
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized			500,000	125,000	11,111
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							611,668	143,027
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value							$ 2.02	$ 4.80
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant							3,575
Allocated Share-based Compensation Expense, Total							$ 1,053,496	$ 786,550
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance							466,341
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options							$ 1,152,367
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition							1 year 164 days

Note 14 - Stock Based Compens_4

Note 14 - Stock Based Compensation - Additional Shares Authorized (Details) - shares	12 Months Ended							84 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2018
The 2010 Stock Option and Incentive Plan [Member]
Total additional shares (in shares)	106,076	12,623	7,257	5,463	4,128	2,871	2,502	140,920

Note 14 - Stock Based Compens_5

Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Total stock compensation expense	$ 1,053,496	$ 786,550
General and Administrative Expense [Member] | Employee Stock Option [Member]
Total stock compensation expense	809,110	621,668
Research and Development Expense [Member] | Employee Stock Option [Member]
Total stock compensation expense	$ 244,386	$ 164,882

Note 14 - Stock Based Compens_6

Note 14 - Stock Based Compensation - Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Expected term (in years) (Year)	10 years
Employee Stock Option [Member] | Minimum [Member]
Risk free interest rate	2.47%	1.86%
Expected term (in years) (Year)	5 years 87 days	5 years 116 days
Expected volatility	108.81%	112.86%
Employee Stock Option [Member] | Maximum [Member]
Risk free interest rate	2.71%	2.04%
Expected term (in years) (Year)	5 years 208 days	6 years 131 days
Expected volatility	126.43%	114.19%

Note 14 - Stock Based Compens_7

Note 14 - Stock Based Compensation - Stock Option Activity (Details) - The 2010 Stock Option and Incentive Plan [Member]	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Outstanding, shares (in shares) | shares	172,510
Outstanding, Weighted average exercise price per share (in dollars per share) | $ / shares	$ 49.27
Granted, shares (in shares) | shares	611,668
Granted, Weighted average exercise price per share (in dollars per share) | $ / shares	$ 2.39
Forfeited, shares (in shares) | shares	(795)
Forfeited, Weighted average exercise price per share (in dollars per share) | $ / shares	$ 562.55
Outstanding, shares (in shares) | shares	783,383
Outstanding, Weighted average exercise price per share (in dollars per share) | $ / shares	$ 12.14
Outstanding, weighted average contractual life remaining in years (Year)	9 years 62 days
Exercisable, shares (in shares) | shares	317,042
Exercisable, Weighted average exercise price per share (in dollars per share) | $ / shares	$ 24.39
Exercisable, weighted average contractual life remaining in years (Year)	8 years 354 days
Vested and expected to vest, shares (in shares) | shares	783,383
Vested and expected to vest, Weighted average exercise price per share (in dollars per share) | $ / shares	$ 12.14
Vested and expected to vest, weighted average contractual life remaining in years (Year)	9 years 62 days

Note 14 - Stock Based Compens_8

Note 14 - Stock Based Compensation - Compensation Expense Related to Liability Grants (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Total stock compensation expense	$ 1,053,496	$ 786,550
Liability Options [Member]
Total stock compensation expense	1,410,025
General and Administrative Expense [Member] | Liability Options [Member]
Total stock compensation expense	869,515
Research and Development Expense [Member] | Liability Options [Member]
Total stock compensation expense	$ 540,510

Note 14 - Stock Based Compens_9

Note 14 - Stock Based Compensation - Valuation Assumptions for Liability Options (Details)	12 Months Ended
	Dec. 31, 2018$ / shares
Expected term (in years) (Year)	10 years
Dividend yield	0.00%
Liability Options [Member]
Dividend yield
Liability Options [Member] | Minimum [Member]
Risk free interest rate	2.51%
Expected term (in years) (Year)	4 years 182 days
Stock price (in dollars per share)	$ 1.02
Expected volatility	122.00%
Liability Options [Member] | Maximum [Member]
Risk free interest rate	2.94%
Expected term (in years) (Year)	5 years
Stock price (in dollars per share)	$ 2.38
Expected volatility	125.00%

Note 15 - Restatement to Prev_3

Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Details Textual) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Preferred Stock, Deemed Dividend	$ 11,479,308	$ 11,479,308	$ 11,479,308	$ 2,568,132
Series B Convertible Preferred Stock [Member]
Deemed Dividend on Series B Convertible Preferred Stock	11,479,308
Previously Reported [Member]
Preferred Stock, Deemed Dividend	4,782,100	$ 4,782,100
Previously Reported [Member] | Series B Convertible Preferred Stock [Member]
Preferred Stock, Deemed Dividend	$ 4,782,100

Note 15 - Restatement to Prev_4

Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements - Restatements (Details) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Deemed dividend attributable to preferred stock	$ (11,479,308)	$ (11,479,308)	$ (11,479,308)	$ (2,568,132)
Net loss applicable to common stockholders	$ (15,621,885)	$ (17,496,267)	$ (22,884,242)	$ (10,690,713)
Loss per common share -basic and diluted (in dollars per share)	$ (5.08)	$ (6.11)	$ (5.50)	$ (10.97)
Conversion of Series B convertible preferred stock to common stock
Additional Paid in Capital, Convertible Preferred Stock [Member]
Issuance of Series B convertible preferred stock, net of issuance costs	$ 6,926,778
Deemed Dividend on Series B convertible preferred stock	11,479,308
Conversion of Series B convertible preferred stock to common stock	(7,821,992)
Additional Paid in Capital, Common Stock [Member]
Issuance of Series B convertible preferred stock, net of issuance costs		$ 5,363,759
Deemed Dividend on Series B convertible preferred stock		(11,479,308)
Conversion of Series B convertible preferred stock to common stock		7,422,013
Previously Reported [Member]
Deemed dividend attributable to preferred stock	(4,782,100)	(4,782,100)
Net loss applicable to common stockholders	$ (8,924,677)	$ (10,799,059)
Loss per common share -basic and diluted (in dollars per share)	$ (2.90)	$ (3.77)
Previously Reported [Member] | Additional Paid in Capital, Convertible Preferred Stock [Member]
Issuance of Series B convertible preferred stock, net of issuance costs	$ 12,290,537
Deemed Dividend on Series B convertible preferred stock	4,782,100
Conversion of Series B convertible preferred stock to common stock	$ (7,056,421)
Previously Reported [Member] | Additional Paid in Capital, Common Stock [Member]
Issuance of Series B convertible preferred stock, net of issuance costs		$ 0
Deemed Dividend on Series B convertible preferred stock		(4,782,100)
Conversion of Series B convertible preferred stock to common stock		$ 6,656,442

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual) - USD ($)	Jan. 13, 2019	Jun. 27, 2018	Jun. 29, 2017	Mar. 25, 2019	Mar. 24, 2019	Dec. 31, 2018	Dec. 31, 2017
Proceeds from Warrant Exercises							$ 749,233
Stock Issued During Period, Shares, New Issues			125,000
Subsequent Event [Member]
Proceeds from Warrant Exercises				$ 11,300,000	$ 11,300,000
Class of Warrant or Right, Retired					2,800,000
Stock Issued During Period, Shares, New Issues					2,800,000
Liability Options [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 2.38
Liability Options [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		2,300,000
Liability Options [Member] | Chief Executive Officer [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	0
Liability Options [Member] | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		700,000
Liability Options [Member] | Chief Financial Officer [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	0
The 2019 Options [Member[
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant						3,575
The 2019 Options [Member[ | Subsequent Event [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 1.36
The 2019 Options [Member[ | Chief Executive Officer [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,300,000
The 2019 Options [Member[ | Chief Financial Officer [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	800,000